Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
22,034 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02489318 | A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC(TITAN) | active not recruiting | Phase 3 | 1,052 | Aragon Pharmaceuticals, Inc.INDUSTRY | 22 | Sep 28, 2026 | clinicaltrials |
| NCT03653507 | A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).(GLOW) | active not recruiting | Phase 3 | 507 |
| Astellas Pharma Global Development, Inc.INDUSTRY |
| 18 |
| Sep 28, 2026 |
| clinicaltrials |
| NCT03734029 | Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] | completed | Phase 3 | 557 | Daiichi SankyoINDUSTRY | 20 | Sep 28, 2026 | clinicaltrials |
| NCT04415853 | Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer | recruiting | Phase 3 | 416 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04487080 | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer(MARIPOSA) | active not recruiting | Phase 3 | 1,074 | Janssen Research & Development, LLCINDUSTRY | 28 | Sep 28, 2026 | clinicaltrials |
| NCT04497844 | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)(AMPLITUDE) | active not recruiting | Phase 3 | 696 | Janssen Research & Development, LLCINDUSTRY | 33 | Sep 28, 2026 | clinicaltrials |
| NCT04660344 | A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy(IMvigor011) | active not recruiting | Phase 3 | 761 | Hoffmann-La RocheINDUSTRY | 23 | Sep 28, 2026 | clinicaltrials |
| NCT04711252 | A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease(SERENA-4) | active not recruiting | Phase 3 | 1,371 | AstraZenecaINDUSTRY | 27 | Sep 28, 2026 | clinicaltrials |
| NCT04793958 | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | active not recruiting | Phase 3 | 461 | Mirati Therapeutics Inc.INDUSTRY | 32 | Sep 28, 2026 | clinicaltrials |
| NCT04883957 | Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies | completed | Phase 1 | 64 | BeiGeneINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04973605 | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 246 | BeOne MedicinesINDUSTRY | 13 | Sep 28, 2026 | clinicaltrials |
| NCT04988295 | A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure(MARIPOSA-2) | active not recruiting | Phase 3 | 776 | Janssen Research & Development, LLCINDUSTRY | 29 | Sep 28, 2026 | clinicaltrials |
| NCT05006716 | A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies(CaDAnCe-101) | recruiting | Phase 1 / Phase 2 | 645 | BeOne MedicinesINDUSTRY | 16 | Sep 28, 2026 | clinicaltrials |
| NCT05048368 | Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function | withdrawn | Phase 1 | 0 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05100862 | A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma(MAHOGANY) | active not recruiting | Phase 3 | 799 | BeOne MedicinesINDUSTRY | 28 | Sep 28, 2026 | clinicaltrials |
| NCT05388669 | A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer(PALOMA-3) | active not recruiting | Phase 3 | 418 | Janssen Research & Development, LLCINDUSTRY | 20 | Sep 28, 2026 | clinicaltrials |
| NCT05424822 | A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | active not recruiting | Phase 1 | 167 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 28, 2026 | clinicaltrials |
| NCT05498428 | A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer(PALOMA-2) | recruiting | Phase 2 | 520 | Janssen Research & Development, LLCINDUSTRY | 12 | Sep 28, 2026 | clinicaltrials |
| NCT05540925 | Vascular Invasion Prediction Via a Multimodal Model Supports Re-staging of Early-stage Hepatocellular Carcinoma | completed | — | 3,650 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05901428 | TCb vs EC-T in High Risk ER+/HER2- Breast Cancer | recruiting | Phase 3 | 1,736 | Fudan UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05932212 | AK104 for Recurrent or Metastatic Vulvar Cancer | terminated | Phase 2 | 20 | AkesoINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05981703 | A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 337 | BeOne MedicinesINDUSTRY | 4 | Sep 28, 2026 | clinicaltrials |
| NCT06073821 | Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) | active not recruiting | Phase 3 | 652 | BeOne MedicinesINDUSTRY | 21 | Sep 28, 2026 | clinicaltrials |
| NCT06095089 | A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer | recruiting | Phase 1 | 355 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 28, 2026 | clinicaltrials |
| NCT06120283 | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 | 433 | BeOne MedicinesINDUSTRY | 11 | Sep 28, 2026 | clinicaltrials |
| NCT06253234 | Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas | active not recruiting | Phase 1 | 12 | Beijing Tiantan HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06619236 | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer(RAINFOL-02) | active not recruiting | Phase 3 | 584 | GenmabINDUSTRY | 18 | Sep 28, 2026 | clinicaltrials |
| NCT06697184 | A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. | recruiting | Phase 1 / Phase 2 | 258 | BeOne MedicinesINDUSTRY | 6 | Sep 28, 2026 | clinicaltrials |
| NCT06742996 | A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) | recruiting | Phase 3 | 300 | BeOne MedicinesINDUSTRY | 17 | Sep 28, 2026 | clinicaltrials |
| NCT06744920 | A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis(RELIEVE) | active not recruiting | Phase 3 | 180 | Novartis PharmaceuticalsINDUSTRY | 20 | Sep 28, 2026 | clinicaltrials |
| NCT06780098 | Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) | recruiting | Phase 2 | 144 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Sep 28, 2026 | clinicaltrials |
| NCT06787339 | Capecitabine in Low Risk Triple Negative Breast Cancer(Calorite) | recruiting | Phase 2 | 198 | Fudan UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06833658 | Effects of Aromatherapy With Essential Oils on Anxiety and Depression in Perioperative Patients With Pancreatic Cancer | completed | N/A | 156 | Peking University First HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06919965 | A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer(MoonRISe-3) | recruiting | Phase 3 | 220 | Janssen Research & Development, LLCINDUSTRY | 15 | Sep 28, 2026 | clinicaltrials |
| NCT06958432 | Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II) | recruiting | Phase 2 / Phase 3 | 430 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06973187 | A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | recruiting | Phase 3 | 500 | BeOne MedicinesINDUSTRY | 24 | Sep 28, 2026 | clinicaltrials |
| NCT06997497 | A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) | recruiting | Phase 3 | 477 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Sep 28, 2026 | clinicaltrials |
| NCT07039474 | The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy | recruiting | — | 120 | Peking University First HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07048353 | CD30 CAR-T in the Treatment of CD30 Positive Lymphoma(CAR-T,MTD) | suspended | Early Phase 1 | 15 | Shandong Qilu Cell Therapy Engineering Technology Co., LtdINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07060807 | A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | recruiting | Phase 3 | 1,000 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 28, 2026 | clinicaltrials |
| NCT07152782 | T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis(THUNDER) | recruiting | Phase 2 | 202 | Fudan UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07180212 | Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer | active not recruiting | N/A | 360 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07181681 | A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 63 | BeOne MedicinesINDUSTRY | 3 | Sep 28, 2026 | clinicaltrials |
| NCT07190248 | A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) | recruiting | Phase 3 | 675 | Merck Sharp & Dohme LLCINDUSTRY | 30 | Sep 28, 2026 | clinicaltrials |
| NCT07221253 | A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)(AB02) | recruiting | Phase 3 | 1,100 | AstraZenecaINDUSTRY | 19 | Sep 28, 2026 | clinicaltrials |
Data updated 20 hours agoSource updated unknownsource: clinicaltrials